Physician

Lee H Bogart, M.D.

According to 2025 Medicare claims, Lee Bogart, M.D. (NPI: 1679554380) practices hematology/oncology in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Delaware, PA. This provider's primary affiliated billing organization is ALLIANCE CANCER SPECIALISTS P.C. (NPI: 1487923686; TIN: 452552343) and primary practice location at 19063-5105.

Bogart's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 626 traditional Medicare patients, billed 104,133 HCPCS/CPT codes, and received $1,462,539 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 786 prescription claims across 151 beneficiaries totaling $2,116,187 in drug costs, led by Ibrance (Palbociclib). 2020 DME data shows 14 claims. Open Payments data shows 17 records totaling $395. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,286,618 to $2,116,187. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	606	114,711	$1,560,079
2016	587	85,174	$1,137,403
2017	550	95,791	$1,271,939
2018	600	105,410	$1,514,689
2019	612	78,652	$1,208,303
2020	564	84,667	$1,155,667
2021	541	82,057	$988,058
2022	542	89,829	$1,309,019
2023	582	88,048	$1,313,896
2024	626	104,133	$1,462,539

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	119	757	$1,286,618
2016	127	700	$1,236,734
2017	123	600	$1,612,110
2018	124	662	$1,342,751
2019	120	725	$1,625,117
2020	137	1,149	$3,472,870
2021	140	1,094	$2,943,912
2022	151	914	$2,608,386
2023	137	716	$1,522,851
2024	151	786	$2,116,187

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	88	$7,257
2016	N/R	12	$451
2017	N/R	22	$4,756
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	14	$2,250
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	150	277	$103
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	358	718	$72
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	340	711	$13
36415	Insertion of needle into vein for collection of blood sample	322	757	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	291	663	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	34	945	$530,827
Revlimid	Lenalidomide	29	812	$468,307
Jakafi	Ruxolitinib Phosphate	13	390	$228,040
Brukinsa	Zanubrutinib	12	360	$170,306
Xarelto	Rivaroxaban	79	3,811	$71,333

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$395	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lee H. Bogart, M.D.?

Tedicare shows public-source Medicare data for Lee H. Bogart, M.D. (NPI 1679554380), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lee H. Bogart, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Lee H. Bogart, M.D.?

Lee H. Bogart, M.D. is linked to ALLIANCE CANCER SPECIALISTS P.C. (billing NPI 1487923686) in the available physician profile data.

Does Lee H. Bogart, M.D. have Open Payments data?

Lee H. Bogart, M.D. has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.